Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia

✍ Scribed by Ursula Vinatzer; Christine Mannhalter; Margit Mitterbauer; Helga Gruener; Hildegard Greinix; Helmut H. Schmidt; Christa Fonatsch; Rotraud Wieser

• Publisher: John Wiley and Sons
• Year: 2002
• Tongue: English
• Weight: 143 KB
• Volume: 36
• Category: Article
• ISSN: 1045-2257
• DOI: 10.1002/gcc.10144

✦ Synopsis

Abstract

The EVI1 gene in chromosome band 3q26 exhibits a number of properties consistent with a role as an oncogene, and its expression is activated in most myeloid leukemia patients with, as well as in a minority of patients without, 3q26 rearrangements. A splice variant of this gene, MDS1/EVI1, acts as its antagonist at least in some tissue culture assays. We established real‐time quantitative reverse transcriptase polymerase chain reaction (RTQ‐RT‐PCR) assays for these mRNA variants to compare their expression levels in a quantitatively reliable manner. EVI1 was overexpressed to highly variable extents in all patients with, as well as in 14% of patients without, 3q26 rearrangements. In some of these samples, MDS1/EVI1 was also transcribed at elevated levels compared to those of healthy controls. However, although the induction of MDS1/EVI1 was comparable to, or higher than, that of EVI1 in three of five samples with a normal EVI1 locus, this was true for only two of 13 patients with a 3q26 aberration. We further provide preliminary evidence that the RTQ‐RT‐PCR assay may be useful for disease monitoring in patients overexpressing EVI1. © 2002 Wiley‐Liss, Inc.